Director/PDMR Shareholding

RNS Number : 6074I

Allergy Therapeutics PLC

14 December 2020

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Director/PDMR Shareholding

The Company was notified on 8 December 2020 that Wild Indigo SA ("Wild Indigo"), a company of which Manuel Llobet, Chief Executive Officer, has indirect interests, transferred 3,125,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") to Mr Llobet for estate planning purposes. The transfer of Ordinary Shares represents approximately 94 per cent. of Mr Llobet's entire holding in the Company.

Mr Llobet is a Director and PDMR and Wild Indigo is deemed to be a person closely associated with Mr Llobet under Article 19 of the EU Market Abuse Regulation 596/2014.

Following the transfer of shares, Mr Llobet 's holding of Ordinary Shares remains unchanged at a total of 3,325,000 Ordinary Shares, representing 0.52 % of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Manuel Llobet
2	Reason for the notification
a)	Position/status	Chief Executive Officer , Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Allergy Therapeutics plc
b)	LEI	213800PQ7AHK7KGVOE23
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	0.1p ordinary shares GB00B02LCQ05
b)	Nature of the transaction	Transfer of shares from Wild Indigo to Manuel Llobet (direct interests)
c)	Price(s) and volume(s)	Price(s) per Ordinary Share Volume(s) N/A - transfer of beneficial interests 3,125,000
d)	Aggregated information	N/A N/A
e)	Date of the transaction	8 December 2020
f)	Place of the transaction	London Stock Exchange - AIM

-  ENDS  -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

END

 

 

DSHBUBDDGUBDGGS